You just read:

BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

News provided by

BerGenBio ASA

02 Apr, 2019, 06:13 BST